Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

New feature:   Introducing the Finviz Matrix

Learn More
Market News Market Pulse Stocks News ETF News Crypto News

Sight Sciences, Inc.

Contributing Author

Recent Articles by Sight Sciences, Inc.

Sep-01
Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference on September 15 SGHT GlobeNewswire
Aug-19
TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease SGHT GlobeNewswire
Aug-05
Sight Sciences Reports Second Quarter 2026 Financial Results SGHT SGHT +27.75% GlobeNewswire
Aug-05
Sight Sciences Announces Aetna Coverage for OMNI and SION Surgical Systems SGHT SGHT +27.75% GlobeNewswire
Aug-04
Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System SGHT GlobeNewswire
Jul-22
Sight Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026 SGHT SGHT -6.56% GlobeNewswire
May-06
Sight Sciences Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Revenue Guidance SGHT SGHT +23.02% GlobeNewswire
Apr-29
Sight Sciences to Present at Two Upcoming Investor Conferences SGHT -8.94% GlobeNewswire
Apr-22
Sight Sciences Announces the Release of its Sustainability Report SGHT GlobeNewswire
Apr-21
Sight Sciences to Report First Quarter 2026 Financial Results on May 6, 2026 SGHT GlobeNewswire
Apr-01
Sight Sciences' Interventional Technologies for Glaucoma and Dry Eye Disease to be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting SGHT GlobeNewswire
Mar-30
Sight Sciences to Present at the 25th Annual Needham Healthcare Conference on April 13th SGHT -5.15% GlobeNewswire
Mar-30
Sight Sciences Secures Order on Post-Trial Motions That Preserves the Jury's Verdict and Awards Monetary Damages to Sight Sciences Against Alcon and its Hydrus Microstent SGHT -5.15% GlobeNewswire
Mar-04
Sight Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Initiates Full Year 2026 Financial Guidance SGHT SGHT -26.80% GlobeNewswire
Feb-18
Sight Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 SGHT GlobeNewswire
Jan-13
Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Highlights SGHT -7.83% GlobeNewswire
Nov-11
New Peer-Reviewed Publications Highlight Effectiveness of OMNI Surgical System with TruSync Technology in Reducing IOP and Medication Usage in Cataract Combination Procedures, Standalone Procedures, and in African Americans SGHT +7.98% GlobeNewswire
Nov-06
Sight Sciences Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance SGHT SGHT +16.40% GlobeNewswire
Nov-06
Sight Sciences Appoints Ali Bauerlein as Chief Operating Officer and Jim Rodberg as Chief Financial Officer SGHT SGHT +16.40% GlobeNewswire
Nov-04
Sight Sciences to Present at Two Upcoming Investor Conferences SGHT GlobeNewswire
Oct-23
Sight Sciences to Report Third Quarter 2025 Financial Results on November 6, 2025 SGHT GlobeNewswire
Oct-17
Sight Sciences Announces Fee Schedule Establishment from Novitas Solutions and First Coast Service Options for the TearCare Interventional Dry Eye Procedure SGHT +35.94% GlobeNewswire
Sep-17
Sight Sciences Announces Publication of a Systematic Literature Review and Meta-Analysis Showing OMNI Surgical System Achieves Clinically Significant, Long-Term Reductions in IOP and Medication Use SGHT GlobeNewswire
Sep-09
Sight Sciences Announces the OMNI Surgical System to be Included in UnitedHealthcare's Expanded Coverage of Glaucoma Surgical Treatments SGHT GlobeNewswire
Sep-02
Sight Sciences Announces Recognition of the TearCare System in TFOS DEWS III Global Dry Eye Guidelines Published in AJO SGHT GlobeNewswire
Aug-26
Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference SGHT GlobeNewswire
Aug-07
Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance SGHT SGHT +19.44% GlobeNewswire
Jul-30
Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease SGHT GlobeNewswire
Jul-29
Sight Sciences Announces the Publication of the 24-Month Results of the SAHARA RCT Demonstrating the Durability of the TearCare Procedure for the Treatment of Dry Eye Disease SGHT GlobeNewswire
Jul-24
Sight Sciences to Report Second Quarter 2025 Financial Results on August 7, 2025 SGHT -5.82% GlobeNewswire
May-14
Sight Sciences to Present at the Stifel 2025 Virtual Ophthalmology Forum on May 27th SGHT GlobeNewswire
May-08
Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance SGHT +5.94% GlobeNewswire
Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)